Tokunaga E - Search Results

1

Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 study.

Yamashita T, Sohn JH, Tokunaga E, Niikura N, Park YH, Lee KS, Chae YS, Xu B, Wang X, Im SA, Li W, Lu YS, Aguilar CO, Nishijima S, Nishiyama Y, Sugihara M, Modi S, Tsurutani J. Yamashita T, et al. Among authors: tokunaga e. Breast Cancer. 2024 Sep;31(5):858-868. doi: 10.1007/s12282-024-01600-7. Epub 2024 Jun 17. Breast Cancer. 2024. PMID: 38884900 Free PMC article. Clinical Trial.

2

Activation of PI3K/Akt signaling and hormone resistance in breast cancer.

Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y. Tokunaga E, et al. Breast Cancer. 2006;13(2):137-44. doi: 10.2325/jbcs.13.137. Breast Cancer. 2006. PMID: 16755107 Free article.

3

Low incidence of methylation of the promoter region of the FANCF gene in Japanese primary breast cancer.

Tokunaga E, Okada S, Kitao H, Shiotani S, Saeki H, Endo K, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Breast Cancer. 2011 Apr;18(2):120-3. doi: 10.1007/s12282-009-0175-z. Epub 2009 Oct 8. Breast Cancer. 2011. PMID: 19813073

4

High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers.

Tokunaga E, Okada S, Yamashita N, Akiyoshi S, Kitao H, Morita M, Kakeji Y, Maehara Y. Tokunaga E, et al. Breast Cancer. 2012 Apr;19(2):161-9. doi: 10.1007/s12282-010-0232-7. Epub 2010 Nov 10. Breast Cancer. 2012. PMID: 21063923

5

Overexpression of metadherin/MTDH is associated with an aggressive phenotype and a poor prognosis in invasive breast cancer.

Tokunaga E, Nakashima Y, Yamashita N, Hisamatsu Y, Okada S, Akiyoshi S, Aishima S, Kitao H, Morita M, Maehara Y. Tokunaga E, et al. Breast Cancer. 2014 May;21(3):341-9. doi: 10.1007/s12282-012-0398-2. Epub 2012 Aug 18. Breast Cancer. 2014. PMID: 22903204

6

Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.

Hisamatsu Y, Tokunaga E, Yamashita N, Akiyoshi S, Okada S, Nakashima Y, Taketani K, Aishima S, Oda Y, Morita M, Maehara Y. Hisamatsu Y, et al. Among authors: tokunaga e. Breast Cancer. 2015 Sep;22(5):520-8. doi: 10.1007/s12282-013-0515-x. Epub 2014 Jan 11. Breast Cancer. 2015. PMID: 24415069

7

Aromatase inhibitors with or without luteinizing hormone-releasing hormone agonist for metastatic male breast cancer: report of four cases and review of the literature.

Kuba S, Ishida M, Oikawa M, Nakamura Y, Yamanouchi K, Tokunaga E, Taguchi K, Esaki T, Eguchi S, Ohno S. Kuba S, et al. Among authors: tokunaga e. Breast Cancer. 2016 Nov;23(6):945-949. doi: 10.1007/s12282-016-0679-2. Epub 2016 Feb 15. Breast Cancer. 2016. PMID: 26879549 Review.

8

Young adult breast cancer patients have a poor prognosis independent of prognostic clinicopathological factors: a study from the Japanese Breast Cancer Registry.

Kataoka A, Iwamoto T, Tokunaga E, Tomotaki A, Kumamaru H, Miyata H, Niikura N, Kawai M, Anan K, Hayashi N, Masuda S, Tsugawa K, Aogi K, Ishida T, Masuoka H, Iijima K, Kinoshita T, Nakamura S, Tokuda Y. Kataoka A, et al. Among authors: tokunaga e. Breast Cancer Res Treat. 2016 Nov;160(1):163-172. doi: 10.1007/s10549-016-3984-8. Epub 2016 Sep 19. Breast Cancer Res Treat. 2016. PMID: 27647460 Free PMC article.

9

Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari).

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yamamoto Y, Ohno S, Toi M. Kawaguchi H, et al. Among authors: tokunaga e. Breast Cancer Res Treat. 2017 Jun;163(3):545-554. doi: 10.1007/s10549-017-4212-x. Epub 2017 Mar 23. Breast Cancer Res Treat. 2017. PMID: 28337663

10

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.

Kawaguchi H, Masuda N, Nakayama T, Aogi K, Anan K, Ito Y, Ohtani S, Sato N, Saji S, Takano T, Tokunaga E, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita H, Yamashita T, Yamamoto Y, Yotsumoto D, Toi M, Ohno S. Kawaguchi H, et al. Among authors: tokunaga e. Curr Med Res Opin. 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426. Epub 2017 Nov 21. Curr Med Res Opin. 2018. PMID: 29095648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

364 results

Search Page

Filters